Compare Recursion Pharmaceuticals Inc (RXRX) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Uranium Energy Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Uranium Energy Corp trades at $9.55 (market cap $4.65B). The key difference: Uranium Energy Corp is far larger — about 3× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| RXRX | UEC | |
|---|---|---|
Market Cap | $1.53B | $4.65B |
Sector | Health | Energy |
52-Week High | $6.79 | $20.14 |
52-Week Low | $2.84 | $8.00 |
Enterprise Value | $946.50M | $4.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Uranium Energy Corp (UEC) trades at $9.40, up 1.29% today, amid bearish technical signals and challenging fundamentals. The stock shows negative profitability with a net income margin of -513.24% and has missed earnings estimates in two of the last three quarters. Recent news highlights operational pressures and strategic positioning in the uranium sector, with analyst sentiment remaining largely positive despite financial headwinds.
The outlook for UEC hinges on execution of its in-situ recovery ramp-up and uranium sales timing. Investment opportunity lies in its debt-free balance sheet and $794 million liquidity, but risks include persistent losses, high valuation multiples, and reliance on uranium price recovery. Wall Street maintains a buy-heavy consensus, suggesting long-term potential if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
